News explainer

Retatrutide Phase 3: up to 28.3% average weight loss at 80 weeks, with a US filing planned for Q1 2027

Key numbers

Result
28.3% average weight loss on the highest dose at 80 weeks in TRIUMPH-1 (70.3 lb), against 2.2% on placebo. Counting everyone who started, including those who stopped: 25.0% against 3.9%.
Date
May 21, 2026 (TRIUMPH-1 topline). Later results on Sep 29 and Oct 28, 2026, and an ObesityWeek session on Nov 15, 2026.
Announced by
Eli Lilly: Lilly press release, May 21, 2026
Note
Status on Nov 20, 2026: not FDA-approved. Lilly plans to submit it to the FDA in Q1 2027.
Eduard Cristea
Eduard Cristea
Published:
Sample vials in a rack on a clinical research lab bench

What happened

On May 21, 2026, Eli Lilly reported topline results from TRIUMPH-1, a Phase 3 trial of retatrutide in 2,339 adults with obesity or overweight and no diabetes. Over 80 weeks, people on the highest dose lost an average of 28.3% of their body weight (70.3 lb), the middle dose 25.9% and the lowest dose 19.0%, against 2.2% on placebo (Lilly). Those figures assume everyone stayed on treatment. Counting everyone who started, the highest dose lost 25.0% against 3.9% on placebo.

45.3% of people on the highest dose lost 30% or more of their body weight. In an extension for 532 people who started with a BMI of 35 or more, weight loss reached up to 30.3% (85.0 lb) at 104 weeks.

Retatrutide is a weekly injection that acts on three hormone receptors: GIP, GLP-1 and glucagon. The most common side effects on the highest dose were nausea (42.4% against 14.8% on placebo), diarrhea (32.0% against 13.5%), constipation (26.1% against 10.9%) and vomiting (25.3% against 4.8%).

More results followed. In TRIUMPH-2, adults with obesity and type 2 diabetes on the highest dose lost 20.8% (49.6 lb) at 80 weeks (Lilly, Sep 29, 2026). On Oct 28, 2026, Lilly reported the first head-to-head trial against Ozempic in type 2 diabetes: 20% to 21% weight loss on retatrutide against 9% on Ozempic at 80 weeks (Lilly). Lilly presented Phase 3 results at ObesityWeek in Washington, D.C. on Nov 15, 2026 (Lilly).

Lilly says retatrutide "is legally available only to participants in Lilly's clinical trials." It is not FDA-approved and cannot be bought from a pharmacy or telehealth program today.

What this means for cost

Retatrutide has no price today because it is not approved. The approved and compounded options below are what people pay now. Zepbound, also made by Lilly, is the closest approved drug: it acts on two of the three receptors retatrutide targets.

Cash prices on our records
OptionCash price on our recordRead
Zepbound (tirzepatide), Eli LillyKwikPen through LillyDirect: from $299 a month at 2.5 mg, $399 at 5 mg, $449 at higher doses.Maker's page, Nov 6, 2026
Wegovy (semaglutide), Novo NordiskPen: $199 a month for the first 2 fills at 0.25 mg or 0.5 mg for new patients, through December 31, 2026, then $349. Pill: $149 at 1.5 mg, $199 at 4 mg, $299 at 9 mg and 25 mg.Maker's page, Nov 6, 2026
Foundayo (orforglipron), Eli LillyThrough LillyDirect: from $149 a month at 0.8 mg and 2.5 mg, $199 at 5.5 mg, $299 at higher doses.Maker's page, Nov 6, 2026
EmbodyCompounded tirzepatide$129/mo, medication plus recorded program feeRecorded Nov 6, 2026
CoreAge RxCompounded tirzepatide$129/mo, medication plus recorded program feeRecorded Nov 6, 2026
Sprout HealthCompounded tirzepatide$199 per 4 weeks, medication plus recorded program feeRecorded Nov 6, 2026
EmbodyCompounded semaglutide$79/mo, medication plus recorded program feeRecorded Nov 6, 2026
CoreAge RxCompounded semaglutide$79/mo, medication plus recorded program feeRecorded Nov 6, 2026
AgelessRxCompounded semaglutide$139/mo, medication plus recorded program feeDate not recorded

Compounded rows are the lowest recorded monthly subtotals among active listings, sorted by price: medication plus any recorded program fee, with other costs such as labs or shipping not included. Compounded medications are not FDA-approved and are not the brand products. Your prescriber decides which drug and strength fit you.

What happens next

  1. Q1 2027

    Lilly plans to submit a Biologics License Application to the FDA (Lilly, Jul 23, 2026). The FDA review starts after that; no decision date exists yet.

  2. Future medical meetings

    Lilly says more detailed results will be presented at medical meetings and published in peer-reviewed journals.

Sources

  1. Eli Lilly, TRIUMPH-1 topline results (May 21, 2026), read Nov 20, 2026
  2. Eli Lilly, TRIUMPH-2 detailed results (Sep 29, 2026), read Nov 20, 2026
  3. Eli Lilly, TRIUMPH-2 and TRIUMPH-3 topline and Q1 2027 filing plan (Jul 23, 2026), read Nov 20, 2026
  4. Eli Lilly press releases: TRANSCEND-T2D-2 head to head with Ozempic (Oct 28, 2026), read Nov 20, 2026
  5. Eli Lilly, ObesityWeek 2026 presentations (Nov 14, 2026), read Nov 20, 2026

Embody

from $49/mo, 12-month plan

Visit Embody